HDAC6 and plasma cell myeloma: Rana et al. identified FDA-approved bioactive molecules that enhanced proteasome activity and demonstrated that histone deacetylase 6 (HDAC6) inhibitors increased proteasomal hydrolysis of small fluorogenic proteasome substrates, increased pan-MHC-I antigen presentation, and enhanced the anti-myeloma cytotoxic activity of autologous patient-derived T-cells [97].